Stoke Therapeutics Taps Veteran RNA Expert as CSO
Event summary
- Stoke Therapeutics appointed Thomas McCauley, Ph.D., as Chief Scientific Officer on July 13, 2026.
- McCauley brings 25 years of experience in R&D and RNA medicine development, including roles at Shire and Neptune Bio.
- He will lead Stoke’s scientific strategy and expand its pipeline beyond Dravet syndrome using the company’s TANGO platform.
- Zorevunersen, Stoke’s lead investigational drug for Dravet syndrome, is in Phase 3 clinical trials.
The big picture
Stoke Therapeutics is doubling down on its RNA medicine platform by bringing in a seasoned executive with deep expertise in rare disease treatments. The move underscores the company’s ambition to become a leader in genetic therapies, particularly for conditions like Dravet syndrome where current treatments fall short. McCauley’s track record suggests Stoke aims to accelerate its pipeline and potentially expand into other severe genetic disorders.
What we're watching
- Pipeline Expansion
- How McCauley’s leadership will accelerate Stoke’s pipeline beyond Dravet syndrome.
- Clinical Progress
- The pace at which zorevunersen advances through Phase 3 trials and potential regulatory approvals.
- Strategic Partnerships
- Whether Stoke’s collaboration with Biogen will expand or evolve under McCauley’s tenure.
Related topics